tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Madrigal Pharmaceuticals Inc

MDGL
Add to Watchlist
461.707USD
-31.404-6.37%
Market hours （ET）Quotes delayed by 15 min
10.64BMarket Cap
LossP/E TTM

Madrigal Pharmaceuticals Inc

461.707
-31.404-6.37%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

MDGL Financials

See Madrigal Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Madrigal Pharmaceuticals Inc Earnings Date

Latest Release
Jul 30, 2026
EPS / Forecast
-1.99/-2.57
Revenue / Forecast
364.25M/353.18M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
958.40M
432.05%
EPS(YoY)
-12.85
41.33%
Analyst Rating
BUY
2026/07/30
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
-4.41%-1.99
---3.25
---2.55
---5.08
---1.90
---3.32
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Revenue
71.17%364.25M
126.84%311.34M
210.77%321.08M
362.03%287.27M
1353.76%212.80M
--137.25M
--103.32M
--62.17M
--14.64M
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Net Profit
-37.03%-57.94M
-28.88%-94.39M
1.42%-58.58M
-6.76%-114.19M
72.18%-42.28M
50.36%-73.24M
47.04%-59.42M
-8.33%-106.96M
-77.12%-151.97M
-91.87%-147.54M
-30.60%-112.19M
-21.61%-98.74M
-21.31%-85.80M
-33.69%-76.90M
-33.08%-85.91M
-28.68%-81.20M
-14.73%-70.73M
-9.46%-57.52M
-9.18%-64.55M
-8.86%-63.10M
Net Margin
19.94%-15.91%
---30.32%
---18.24%
---39.75%
---19.87%
---53.36%
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Gross Margin
-7.02%89.02%
--91.38%
--92.39%
--93.69%
--95.74%
--96.71%
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Debt to assets ratio
134.86%27.38%
--27.73%
--26.98%
--24.94%
--11.66%
--11.84%
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income Statement
Revenue
71.17%364.25M
126.84%311.34M
210.77%321.08M
362.03%287.27M
1353.76%212.80M
--137.25M
--103.32M
--62.17M
--14.64M
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Operating profit
-19.29%-56.31M
-16.91%-92.72M
11.03%-59.61M
2.00%-113.97M
70.96%-47.20M
47.83%-79.31M
42.82%-67.00M
-18.03%-116.30M
-88.01%-162.54M
-94.08%-152.04M
-37.37%-117.18M
-22.54%-98.53M
-23.02%-86.45M
-36.03%-78.34M
-32.04%-85.30M
-27.31%-80.41M
-13.82%-70.27M
-8.70%-57.59M
-8.47%-64.60M
-7.44%-63.16M
Net Profit
-37.03%-57.94M
-28.88%-94.39M
1.42%-58.58M
-6.76%-114.19M
72.18%-42.28M
50.36%-73.24M
47.04%-59.42M
-8.33%-106.96M
-77.12%-151.97M
-91.87%-147.54M
-30.60%-112.19M
-21.61%-98.74M
-21.31%-85.80M
-33.69%-76.90M
-33.08%-85.91M
-28.68%-81.20M
-14.73%-70.73M
-9.46%-57.52M
-9.18%-64.55M
-8.86%-63.10M
Balance Sheet
Current assets
19.52%1.20B
19.67%1.18B
20.61%1.25B
26.61%1.35B
-8.09%1.00B
-8.01%987.98M
62.08%1.03B
351.72%1.06B
261.98%1.09B
224.18%1.07B
76.35%637.28M
49.87%235.47M
40.57%301.60M
49.79%331.28M
33.01%361.37M
-48.14%157.11M
-34.20%214.55M
-28.20%221.17M
-4.73%271.68M
-10.26%302.96M
Total current liabilities
90.43%374.20M
102.26%338.26M
83.30%310.29M
120.08%391.41M
57.00%196.50M
46.26%167.24M
42.79%169.28M
78.44%177.85M
25.53%125.16M
16.26%114.34M
2.29%118.55M
0.75%99.67M
18.68%99.71M
28.33%98.35M
50.83%115.89M
42.69%98.92M
48.14%84.01M
57.07%76.64M
65.04%76.84M
40.43%69.33M
Total assets
22.58%1.24B
23.15%1.23B
20.85%1.26B
26.95%1.36B
-7.67%1.02B
-7.91%996.63M
62.71%1.04B
351.02%1.07B
263.61%1.10B
225.55%1.08B
76.67%640.55M
50.00%237.96M
39.77%302.46M
49.31%332.45M
32.65%362.57M
-47.93%158.64M
-34.02%216.39M
-28.11%222.66M
-4.76%273.33M
-10.28%304.70M
Total liabilities
125.71%720.92M
139.12%683.87M
128.20%656.90M
148.80%736.73M
31.62%319.40M
23.53%285.99M
22.38%287.86M
37.27%296.11M
21.97%242.67M
26.99%231.52M
42.40%235.21M
45.78%215.72M
49.75%198.96M
137.02%182.31M
113.90%165.18M
111.95%147.97M
131.85%132.86M
56.41%76.92M
64.22%77.22M
39.88%69.82M
Total equity
-24.75%523.72M
-23.53%543.45M
-20.11%602.69M
-19.48%625.73M
-18.80%695.98M
-16.47%710.64M
86.11%754.38M
3392.99%777.15M
728.09%857.12M
466.66%850.76M
105.35%405.33M
108.52%22.25M
23.91%103.51M
3.01%150.14M
0.65%197.39M
-95.46%10.67M
-69.14%83.53M
-44.06%145.74M
-18.28%196.11M
-18.92%234.88M
Cash Flow Statement
Net operating income
149.58%23.33M
-88.36%-167.44M
-27.73%-133.46M
219.21%79.85M
65.13%-47.05M
40.40%-88.89M
-30.72%-104.49M
21.12%-66.98M
-79.19%-134.94M
-77.43%-149.16M
-36.60%-79.93M
-43.76%-84.92M
-31.29%-75.31M
-68.43%-84.07M
-21.78%-58.52M
-29.66%-59.07M
-22.35%-57.36M
-14.93%-49.91M
12.55%-48.05M
4.79%-45.56M
Net investment
-28.55%34.20M
17.28%192.19M
157.52%27.58M
-2.28%-207.00M
139.20%47.86M
67.13%163.88M
86.76%-47.95M
-503.18%-202.39M
-3171.65%-122.10M
152.47%98.05M
-645.47%-362.12M
-22.93%50.20M
-119.40%-3.73M
-434.13%-186.86M
324.39%66.39M
62.47%65.14M
170.40%19.24M
267.12%55.93M
426.03%15.64M
-57.69%40.09M
Net financing
78.75%3.11M
-73.04%2.33M
-54.70%8.96M
3071.36%236.65M
-98.70%1.74M
-98.49%8.64M
-95.88%19.77M
-61.89%7.46M
212.42%134.12M
988.83%573.71M
81.55%479.92M
--19.58M
-12.59%42.93M
--52.69M
1255.37%264.34M
-100.00%0.00
-22.71%49.11M
-100.00%0.00
321.32%19.50M
5928.29%21.10M

FAQs

What is the total revenue of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 958.40M, with a year-on-year change of 180.13M.

What are the current assets of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its current assets were 1.25B, with a year-on-year change of 20.61.

What are the total assets of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its total assets of Madrigal Pharmaceuticals Inc were 1.26B, with a year-on-year change of 20.85.

What are the total liabilities of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Madrigal Pharmaceuticals Inc were 656.90M, with a year-on-year change of 128.20.

What is the total equity of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its total equity of Madrigal Pharmaceuticals Inc was 602.69M, with a year-on-year change of -20.11.

What is the net operating income of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Madrigal Pharmaceuticals Inc was -300.10M, with a year-on-year change of 39.72.

What is the net investment of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its net investment of Madrigal Pharmaceuticals Inc was 32.32M, with a year-on-year change of 111.78.

What is the net financing of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its net financing of Madrigal Pharmaceuticals Inc was 255.98M, with a year-on-year change of -65.18.

What is the Earnings Per Share (EPS) of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -12.85, with a year-on-year change of 41.33.

What is the net income of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its net income was -288.28M, with a year-on-year change of 38.12.

What is the net margin of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was -30.08, with a year-on-year change of 88.37.

What is the gross margin of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 94.14, with a year-on-year change of -2.48.

What is the debt-to-asset ratio of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 26.98, with a year-on-year change of 139.21.

What is the Return on Equity (ROE) of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was -42.49, with a year-on-year change of 47.12.

What is the Return on Assets (ROA) of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was -25.05, with a year-on-year change of 54.76.

What is the operating profit of Madrigal Pharmaceuticals Inc?

According to Madrigal Pharmaceuticals Inc's FY2025 earnings report, its operating profit was -300.10M, with a year-on-year change of 39.72.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy